1. Home
  2. CLRB vs DPRO Comparison

CLRB vs DPRO Comparison

Compare CLRB & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLRB
  • DPRO
  • Stock Information
  • Founded
  • CLRB 2002
  • DPRO 1998
  • Country
  • CLRB United States
  • DPRO Canada
  • Employees
  • CLRB N/A
  • DPRO N/A
  • Industry
  • CLRB Biotechnology: Pharmaceutical Preparations
  • DPRO Aerospace
  • Sector
  • CLRB Health Care
  • DPRO Industrials
  • Exchange
  • CLRB Nasdaq
  • DPRO Nasdaq
  • Market Cap
  • CLRB 17.6M
  • DPRO 36.2M
  • IPO Year
  • CLRB N/A
  • DPRO N/A
  • Fundamental
  • Price
  • CLRB $5.03
  • DPRO $3.12
  • Analyst Decision
  • CLRB Hold
  • DPRO Strong Buy
  • Analyst Count
  • CLRB 2
  • DPRO 2
  • Target Price
  • CLRB N/A
  • DPRO $5.25
  • AVG Volume (30 Days)
  • CLRB 278.7K
  • DPRO 2.5M
  • Earning Date
  • CLRB 08-12-2025
  • DPRO 08-12-2025
  • Dividend Yield
  • CLRB N/A
  • DPRO N/A
  • EPS Growth
  • CLRB N/A
  • DPRO N/A
  • EPS
  • CLRB N/A
  • DPRO N/A
  • Revenue
  • CLRB N/A
  • DPRO $4,716,450.00
  • Revenue This Year
  • CLRB N/A
  • DPRO $94.01
  • Revenue Next Year
  • CLRB N/A
  • DPRO $95.14
  • P/E Ratio
  • CLRB N/A
  • DPRO N/A
  • Revenue Growth
  • CLRB N/A
  • DPRO 7.90
  • 52 Week Low
  • CLRB $4.36
  • DPRO $1.55
  • 52 Week High
  • CLRB $94.50
  • DPRO $6.09
  • Technical
  • Relative Strength Index (RSI)
  • CLRB 32.91
  • DPRO 58.98
  • Support Level
  • CLRB $4.36
  • DPRO $2.96
  • Resistance Level
  • CLRB $8.30
  • DPRO $3.32
  • Average True Range (ATR)
  • CLRB 1.28
  • DPRO 0.29
  • MACD
  • CLRB -0.72
  • DPRO 0.04
  • Stochastic Oscillator
  • CLRB 4.81
  • DPRO 81.48

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

Share on Social Networks: